Skip to Main Content

1,505

Views

0

CrossRef citations to date

0

Altmetric

Research Article

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Adelaide A. Heberta UTHealth McGovern Medical School, Houston, Texas, USACorrespondence[email protected]
View further author information

,

Carsten Flohrb St John’s Institute of Dermatology, King’s College London, London, UKView further author information

,

H. Chih-ho Hongc University of British Columbia, and Probity Medical Research, Surrey, British Columbia, CanadaView further author information

,

Alan D. Irvined Clinical Medicine, Trinity College Dublin, Dublin, IrelandView further author information

,

Evangeline Piercee Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

,

Hany Elmaraghye Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

,

Sreekumar Pillaie Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

,

Zach Dawsone Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

,

Sherry Chenf Tigermed, Somerset, New Jersey, USAView further author information

,

Clara Armengolg Almirall S.A., Barcelona, SpainView further author information

,

Elaine Siegfriedh Saint Louis University, St. Louis, Missouri, USAView further author information

&

Stephan Weidingeri University Hospital Schleswig-Holstein, Kiel, GermanyView further author information